Fiche société
GuangZhou Cellgenes Biotechnology Co., Ltd.
Traitements, essais et publications liés.
Traitements7programmes
Essais1liés
Publications3liées
SourceDBlocale
Traitements
7| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| 1.0 × 10^6 cells/kg once every two weeks for a total of 3 doses1. To evaluate the safety and tolerability of CG-BM1 for the treatment of patients with Ischemic Stroke. 2. To observe the preliminary effectiveness of CG-BM1 in treating Ischemic Stroke patients. | Accident vasculaire cérébral | Phase 1/2 | À vérifier | China | À vérifier |
| 2.0 × 10^6 cells/kg once every two weeks for a total of 3 doses1. To evaluate the safety and tolerability of CG-BM1 for the treatment of patients with Ischemic Stroke. 2. To observe the preliminary effectiveness of CG-BM1 in treating Ischemic Stroke patients. | Accident vasculaire cérébral | Phase 1/2 | À vérifier | China | À vérifier |
| 3.0 × 10^6 cells/kg once every two weeks for a total of 3 doses1. To evaluate the safety and tolerability of CG-BM1 for the treatment of patients with Ischemic Stroke. 2. To observe the preliminary effectiveness of CG-BM1 in treating Ischemic Stroke patients. | Accident vasculaire cérébral | Phase 1/2 | À vérifier | China | À vérifier |
| single infusion, 1.0 × 10^6 cells/kg1. To evaluate the safety and tolerability of CG-BM1 for the treatment of patients with Ischemic Stroke. 2. To observe the preliminary effectiveness of CG-BM1 in treating Ischemic Stroke patients. | Accident vasculaire cérébral | Phase 1/2 | À vérifier | China | À vérifier |
| single infusion, 2.0 × 10^6 cells/kg1. To evaluate the safety and tolerability of CG-BM1 for the treatment of patients with Ischemic Stroke. 2. To observe the preliminary effectiveness of CG-BM1 in treating Ischemic Stroke patients. | Accident vasculaire cérébral | Phase 1/2 | À vérifier | China | À vérifier |
| single infusion, 3.0 × 10^6 cells/kg1. To evaluate the safety and tolerability of CG-BM1 for the treatment of patients with Ischemic Stroke. 2. To observe the preliminary effectiveness of CG-BM1 in treating Ischemic Stroke patients. | Accident vasculaire cérébral | Phase 1/2 | À vérifier | China | À vérifier |
| single infusion, 1.0 × 10^6 cells/kg1. To evaluate the safety and tolerability of CG-BM1 for the treatment of patients with Ischemic Stroke. 2. To observe the preliminary effectiveness of CG-BM1 in treating Ischemic Stroke patients. | Accident vasculaire cérébral | Phase 1/2 | À vérifier | China | À vérifier |
Essais cliniques
1| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| single infusion, 1.0 × 10^6 cells/kg | Accident vasculaire cérébral | Phase 1/2 | NCT07896941 | Safety and Efficacy of CG-BM1 in Ischemic Stroke | RECRUITING |
Publications
3| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| single infusion, 3.0 × 10^6 cells/kg | Safety and efficacy of human umbilical cord mesenchymal stem cells for the treatment of sepsis induced by pneumonia: study protocol for a single-centre, randomised single-blind parallel group trial. | BMJ open | ||
| single infusion, 3.0 × 10^6 cells/kg | Safety and tolerability of bone marrow-derived mesenchymal stem cells in lupus animal models and a phase I clinical trial in humans. | Lupus | ||
| single infusion, 3.0 × 10^6 cells/kg | C-CAR066, a novel fully human anti-CD20 CAR-T therapy for relapsed or refractory large B-cell lymphoma after failure of anti-CD19 CAR-T therapy: A phase I clinical study. | American journal of hematology |